CVS Health pharmacy business performs strongly, quarterly profit exceeds expectations
Special Report: Focus on US Stocks Q4 2025 Earnings
CVS Health announced on Tuesday that its fourth-quarter profits declined, but strong performance in its pharmacy benefit management division and an increase in retail pharmacy prescription volumes led to results that exceeded Wall Street expectations.
According to data from London Stock Exchange Group (LSEG), CVS's quarterly adjusted earnings per share fell from $1.19 to $1.09, higher than analysts' average expectation of $0.99.
The company's Chief Financial Officer, Brian Newman, stated: "I often talk about the 'say-do ratio'—we set pragmatic goals and strive to meet or even exceed expectations."
Newman noted that profits from the pharmacy business had declined by about 5% annually over the past five years, but after acquiring certain assets from Rite Aid, which had filed for bankruptcy, profits in that segment are expected to grow by 5% in 2025.
This healthcare group maintained its full-year 2026 adjusted earnings per share forecast at $7.00 to $7.20, consistent with the previous quarter. LSEG data shows analysts' average expectation is $7.17 per share.
CVS owns large US pharmacy chains, Aetna insurance, and CVS Caremark pharmacy benefit management company. After several quarters of underperformance and management changes in 2024, the company undertook cost-cutting and business restructuring in 2025.
Prescription Volume Growth Drives Revenue Increase
Driven by factors such as the Rite Aid acquisition, fourth-quarter total revenue rose from $97.7 billion to $105.7 billion, with prescription volume up 6.3% year-over-year.
The health services segment, which includes the Caremark pharmacy benefit management division, saw its fourth-quarter revenue rise from $47 billion in the same period last year to $51.2 billion.
Impacted by policies related to the Inflation Reduction Act, Aetna's medical loss ratio (the proportion of premiums spent on medical services) was 94.8%, lower than analysts' expectation of 95.5%.
Newman said that this legislation, enacted during the Biden administration, caused a sharp rise in medical costs for the company's Medicare Advantage business in the second half of last year.
Insurance companies specializing in Medicare (the US government health insurance program for seniors and disabled individuals) are facing revenue pressures due to increased demand for medical services and adjustments to government reimbursement policies.
Last month, the Trump administration proposed that the 2027 payment increases for Medicare Advantage plans would be much lower than expected, causing stocks of companies such as CVS, UnitedHealth Group, and Humana to fall.
In 2025, CVS announced it would stop offering insurance plans related to the Affordable Care Act, stating that the business was no longer sustainable.
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Rejects Iran's Proposal for Talks; Global Stocks and Bonds Under Pressure, Oil Prices Up Over 2%, Gold Falls Below 4200
Trump rejected Iran's latest proposal to reopen the Strait of Hormuz, causing the optimistic sentiment in the market last Friday to quickly reverse amidst the Middle East diplomatic stalemate. Brent crude oil rose over 2%, gold fell below $4,200, and silver dropped more than 4%. Asia-Pacific stock markets broadly declined, with South Korea's KOSPI falling over 2%. Global bond markets came under pressure, and the yield on the US 2-year Treasury rose to 4.90%. Market focus will shift to this week's PCE inflation data and the non-farm payroll report.
Indian Rupee starts the week negatively amid higher oil prices
AI demand drives TSMC to accelerate capacity expansion, 2nm monthly production aims for 120,000 wafers by year-end
According to reports, industry giants such as Apple, Nvidia, and AMD have collectively increased their orders by 10% to 20%, directly boosting TSMC's 2nm monthly production capacity to 120,000 wafers by the end of the year, which exceeds the previous estimate by more than 20% and brings forward the 2027 target by two years. For the first time in history, five factories will ramp up production simultaneously, and the annual compound growth rate of capacity from 2026 to 2028 will reach as high as 70%.
Long-term US Treasury Sell-off Continues! 10-Year Treasury Yield Breaks 5.2% Again, “AI Boom vs. Rising Financing Costs” Narrative Showdown Intensifies
On Monday, oil prices rose and US Treasury bonds were sold off again as former US President Donald Trump rejected Iran's latest proposal to reopen the Strait of Hormuz, heightening concerns about inflation.
Crypto prices
More
